Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study-Reference-Cited by-同舟云学术

Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study

Published:2018-11 Issue:2 Volume:151 Page:257-263
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Tew William P.,Sill Michael W.,Walker Joan L.,Secord Angeles Alvarez,Bonebrake Albert J.,Schilder Jeanne M.,Stuckey Ashley,Rice Laurel,Tewari Krishnansu S.^ORCID,Aghajanian Carol A.

Funder

National Cancer Institute

Memorial Sloan Kettering Cancer Center

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference27 articles.

1. Markedly elevated levels of vascular endothelial growth factor in malignant ascites;Zebrowski;Ann. Surg. Oncol.,1999

2. Prognostic significance of VEGF expression in human ovarian carcinoma;Shen;Br. J. Cancer,2000

3. Serum VEGF in epithelial ovarian neoplasms: correlation with patient survival;Chen;Gynecol. Oncol.,1999

4. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study;Burger;J. Clin. Oncol.,2007

5. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer;Cannistra;J. Clin. Oncol.,2007

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A new perspective on antiangiogenic antibody drug resistance: Biomarkers, mechanisms, and strategies in malignancies;Drug Development Research;2024-09

2. COL6A3 Exosomes Promote Tumor Dissemination and Metastasis in Epithelial Ovarian Cancer;International Journal of Molecular Sciences;2024-07-25

3. A systematic review of ethnic minority participation in randomised controlled trials of systemic therapies for gynecological cancers;Gynecologic Oncology;2024-05

4. New clinical trial design in precision medicine: discovery, development and direction;Signal Transduction and Targeted Therapy;2024-03-04

5. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-04-18